by The U.S. inflammatory bowel disease treatment market size was estimated at USD 11.44 billion in 2023 and it is expected to surpass around USD 14.67 billion by 2033, poised to grow at a CAGR of 2.52% from 2024 to 2033.
The U.S. IBD treatment market is a significant segment within the healthcare industry, driven by the increasing prevalence of IBD and advancements in treatment options. It includes pharmaceuticals, biologics, surgical interventions, and supportive therapies aimed at managing symptoms and improving patient outcomes.
Key Highlights:
- Crohn’s Takes Center Stage: Crohn’s disease dominated the market in 2023, holding a substantial 63% revenue share.
- Ulcerative Colitis on the Rise: While Crohn’s disease currently leads, ulcerative colitis is expected to experience the fastest growth rate (CAGR) throughout the forecast period.
- TNF Inhibitors Reign Supreme: TNF inhibitors secured the top spot in 2023, capturing the largest market share among drug classes.
- Injectables Lead the Way: Injectables were the preferred route of administration in 2023, holding the highest market share.
- Oral Medications Gaining Ground: The future looks bright for oral medications, which are projected to witness the fastest growth rate (CAGR) from 2024 to 2033.
- Hospitals Hold the Fort: Hospital pharmacies were the primary source for Crohn’s disease medications in 2023, contributing the largest market share.
- Online Pharmacies on the Upswing: Online pharmacies are anticipated to experience the fastest growth rate (CAGR) in terms of distribution channels from 2024 to 2033.
Inflammatory Bowel Disease (IBD) is a chronic inflammatory condition of the gastrointestinal tract, primarily encompassing Crohn’s disease and ulcerative colitis. It affects millions of individuals globally, with varying degrees of severity and impact on quality of life.
Get a Sample@ https://www.visionresearchreports.com/report/sample/41360
Types of Treatments
1. Pharmaceutical Therapies
- Aminosalicylates: Anti-inflammatory drugs used to treat mild to moderate cases of ulcerative colitis.
- Corticosteroids: Potent anti-inflammatory drugs used for short-term management of moderate to severe IBD flare-ups.
- Immunomodulators: Drugs that suppress the immune system to reduce inflammation and maintain remission.
2. Biologic Therapies
- Anti-TNF Biologics: Target tumor necrosis factor (TNF) to reduce inflammation in moderate to severe cases of Crohn’s disease and ulcerative colitis.
- Interleukin Inhibitors: Biologics targeting interleukin proteins involved in the inflammatory process.
3. Surgical Interventions
- Colectomy: Surgical removal of part or all of the colon in severe cases of ulcerative colitis.
- Strictureplasty: Surgical procedure to widen strictures in the intestines caused by Crohn’s disease.
U.S. Inflammatory Bowel Disease Treatment Market Growth Factors:
- Increasing Prevalence of IBD: The rising incidence of IBD among both adults and children contributes to market growth.
- Advancements in Biologic Therapies: Novel biologic treatments with improved efficacy and safety profiles drive market expansion.
- Patient Education and Awareness: Greater awareness about IBD symptoms and treatment options leads to early diagnosis and intervention.
U.S. Inflammatory Bowel Disease Treatment Market Challenges:
- High Cost of Biologic Therapies: Affordability and access issues pose challenges for patients requiring long-term biologic treatments.
- Adverse Effects: Side effects associated with immunosuppressive therapies require careful management and monitoring.
U.S. Inflammatory Bowel Disease Treatment Market Future Trends:
- Personalized Medicine: Tailoring treatment strategies based on individual patient profiles and genetic markers.
- Emerging Therapies: Development of novel therapies targeting specific pathways involved in IBD inflammation.
- Digital Health Solutions: Integration of telemedicine and digital platforms for remote patient monitoring and support.
Read More@ https://www.heathcareinsights.com/u-s-oligonucleotide-synthesis-market/
U.S. Inflammatory Bowel Disease Treatment Market Top Companies
- Biogen
- Novartis AG
- Eli Lilly and Company
- UCB S.A.
- Celltrion Inc.
- Merck & Co., Inc.
- Johnson & Johnson Services, Inc
Recent Market News
- In October 2023, the FDA granted approval to Novartis for Cosentyx, marking the introduction of the first new biologic treatment option for adult patients with hidradenitis suppurativa.
- In May 2023, Amgen and Tscan Therapeutics joined forces to identify novel targets for Crohn’s disease integration. This collaboration resulted in the development of a platform facilitating target discovery, thereby enhancing Amgen’s expertise and capabilities in inflammation therapeutics.
- In December 2021, Novartis announced FDA approval of Cosentyx for the treatment of active enthesitis-related arthritis. These regulatory milestones played a pivotal role in expanding the market’s share.
- In April 2021, the FDA approved Bristol Myers Squibb’s Zeposia (ozanimod), an oral treatment indicated for adults with active ulcerative colitis
U.S. Inflammatory Bowel Disease Treatment Market Segmentation:
By Type
- Crohn’s Disease
- Ulcerative Colitis
By Drug Class
- Aminosalicylates
- Corticosteroids
- TNF inhibitors
- IL inhibitors
- Anti-integrin
- JAK inhibitors
- Others
By Route of Administration
- Oral
- Injectable
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By Region
- West
- Midwest
- Northeast
- Southwest
- Southeast
Buy this Premium Research Report@ https://www.visionresearchreports.com/report/checkout/41360
You can place an order or ask any questions, please feel free to contact sales@visionresearchreports.com| +1 650-460-3308
